08/02/2019 (Agence Europe) – Stefan Oschmann, President of the European Federation of Pharmaceutical Industries and Associations (EFPIA), wrote a letter on Tuesday 5 February, in which he expressed deep concern about the European Parliament’s recent position on the revision of the Supplementary Protection Certificate (SPC) (see EUROPE 12178). For the President, “the compromise provisions proposed by the European Parliament diverge significantly from the limited scope of the initial proposal by the European Commission and undermine the strong and reliable intellectual property rights in Europe”. At issue is the call for introduction of generic and biosimilar stockpiling in Europe two years before SPC expiry which has not been subject to any “impact assessment”, according to him, and which could undermine intellectual property rights within the Union. To consult the letter: https://bit.ly/2WSxeUT. (PH)